"目录号: HY-15295
Membrane Transporter/Ion Channel-
TAK-438是钾竞争性的酸阻滞剂，能可逆的抑制H_addition_/K_addition_-ATPase，IC50为19 nM(pH 6.5)。
Proton Pump
相关产品
Omeprazole-Pantoprazole sodium-(R)-Lansoprazole-Zinc Pyrithione-AZD0865-Ilaprazole-Esomeprazole Magnesium trihydrate-TAK-438 free base-Bamaquimast-Rabeprazole sodium-Soraprazan-Chebulinic acid-Picoprazole-SKF96067-Tenatoprazole sodium-
生物活性
Description
TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion.IC50 value: 19 nM [1]Target: H+/K+ATPasein vitro: TAK-438 is a pyrrole derivative with a chemical structure that is completely different from the P-CABs developed to date. TAK-438 inhibits gastric H+, K+-ATPase activity in a concentration-dependent manner. Under neutral conditions (pH 7.5), the inhibitory activity of TAK-438 is almost the same as that under weakly acidic conditions (pH 6.5). TAK-438 does not inhibit Na+, K+-ATPase activity even at concentration 500 times higher than their IC50 values against gastric H+,K+-ATPase activity. TAK-438 inhibits gastric H+, K+-ATPase in a K+-competitive manner with Ki of 3 nM [2]. in vivo: TAK-438 inhibits basal gastric acid secretion in a dose-dependent manner, and the ID50 value is 1.26 mg/kg . Intravenous administration of TAK-438 dose-dependently increases the pH of the gastric perfusate, and the increase in pH is sustained for 5 h after administration. At the 1 mg/kg dose, the pH plateaues 90 min after administration, and the highest pH value reached is 5.9 [2]. In addition, TAK-438 shows a potent and longer-lasting inhibitory effect on the histamine-stimulated gastric acid secretion in rats and dogs. TAK-438 shows significant antisecretory activity through high accumulation and slow clearance from the gastric tissue. TAK-438 is unaffected by the gastric secretory state, unlike PPIs [3].
Clinical Trial
NCT02141711
Takeda
Erosive Esophagitis(EE)-Gastroesophageal Reflux Disease (GERD)
October 2008
Phase 1
NCT02774902
Takeda
Healthy Volunteers
August 2010
Phase 1
NCT03085836
Takeda
Healthy Participants
April 25, 2017
Phase 1
NCT01452776
Takeda
Erosive Esophagitis
September 2011
Phase 3
NCT02123953
Takeda
Dose Finding Study
October 2008
Phase 1
NCT02123927
Takeda
Ascending Single Dose Study
September 2007
Phase 1
NCT02954848
Takeda
Non-erosive Gastroesophageal Reflux Disease
December 1, 2016
Phase 3
NCT01459367
Takeda
Erosive Esophagitis
October 2011
Phase 3
NCT02141698
Takeda-Richmond Pharmacology Limited
Dose Finding Study
October 2007
Phase 1
NCT02892409
Takeda
Helicobacter Pylori
September 21, 2016
Phase 1
NCT01474369
Takeda
Non-erosive Gastroesophageal Reflux Disease
December 2011
Phase 3
NCT01505127
Takeda
H. Pylori Infection
January 2012
Phase 3
NCT01452698
Takeda
Erosive Esophagitis
Phase 3
NCT01452711
Takeda
Gastric Ulcer
November 2011
Phase 3
NCT03050307
Takeda
Gastric Ulcer-Peptic Ulcer-Gastrointestinal Diseases-Digestive System Diseases-Lansoprazole-Anti-Ulcer Agents-Gastrointestinal Agents-Proton Pump Inhibitors-Enzyme Inhibitors-Molecular Mechanisms of Pharmacological Action
April 17, 2017
Phase 3
NCT03050359
Takeda
Duodenal Ulcer
April 4, 2017
Phase 3
NCT01452724
Takeda
Duodenal Ulcer
October 2011
Phase 3
NCT01568398
Takeda
Gastric Ulcer-Duodenal Ulcer
May 2012
Phase 3
NCT01568385
Takeda
Gastric Ulcer-Duodenal Ulcer
April 2012
Phase 3
NCT01452763
Takeda
Gastric Ulcers-Duodenal Ulcers
October 2011
Phase 3
NCT01456247
Takeda
Gastric Ulcers-Duodenal Ulcers
March 2012
Phase 3
NCT01452750
Takeda
Gastric Ulcers-Duodenal Ulcers
October 2011
Phase 3
NCT01456260
Takeda
Gastric Ulcers-Duodenal Ulcers
September 2011
Phase 3
NCT01630746
Takeda
Erosive Esophagitis
July 2012
Phase 3
NCT03116841
Takeda
Reflux Esophagitis
April 21, 2017
Phase 4
NCT02679508
Takeda
Erosive Esophagitis
March 29, 2016
Phase 4
NCT02743949
Takeda
Gastroesophageal Reflux
July 14, 2016
Phase 2
NCT03214198
Takeda
A History of Gastric or Duodenal Ulcers
September 1, 2016
NCT03214094
Takeda
Gastric or Duodenal Ulcers
September 1, 2016
NCT03214952
Takeda
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
March 1, 2016
NCT03214081
Takeda
Reflux Esophagitis
March 1, 2016
NCT02827942
Hamamatsu University
Gastritis Associated With Helicobacter Pylori
July 2016
Phase 3
NCT02388724
Takeda
Erosive Esophagitis
March 16, 2015
Phase 3
NCT02388737
Takeda
Erosive Esophagitis
April 2015
Phase 3
NCT02037477
Takeda
Healthy Volunteers
January 2014
Phase 3
NCT03219723
Takeda
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
September 1, 2015
View MoreCollapse
References
[1].Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456.
[2].Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238.
[3].Hori Y, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther, 2011, 337(3), 797-804.